Publications in VIVO

Co-author Network

Audrey D. Zhang, MD

Person

Positions

Resident, Duke University Health System

Location

Durham, NC

Clinical Disciplines

Internal Medicine

Publications
Other
View All

Selected Publications

article
1. Initiation and Persistence of Antipsychotic Medications at Hospital Discharge Among Community-Dwelling Veterans With Dementia.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2024
2. Factors influencing central nervous system medication deprescribing and behavior change in hospitalized older adults.. Journal of the American Geriatrics Society. 72:2359-2371. 2024
3. Temporary FDA Advisory Committee Members, Recommendations, and Agency Actions, 2017-2021.. JAMA Network Open. 2024
4. Demographic characteristics of participants in clinical trials to treat Alzheimer disease, 2008-2023.. Journal of the American Geriatrics Society. 72:942-945. 2023
5. Clinical trial data sharing: a cross-sectional study of outcomes associated with two U.S. National Institutes of Health models.. Scientific data. 10:-. 2023
6. Long-Term Prognosis of Patients With Coexisting Obesity and Malnutrition After Acute Myocardial Infarction: A Cohort Study.. Circulation. Cardiovascular quality and outcomes. 16:-. 2023
7. Consistency between trials presented at conferences, their subsequent publications and press releases.. BMJ evidence-based medicine. 28:95-102. 2022
8. Comparison of Industry Payments to Physicians and Advanced Practice Clinicians. JAMA. 2022
9. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.. JAMA network open. 4:-. 2021
10. Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration.. Journal of general internal medicine. 36:3281-3284. 2021
11. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.. JAMA network open. 4:-. 2021
12. Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review.. JAMA network open. 4:-. 2021
13. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.. Clinical trials (London, England). 18:488-499. 2021
14. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics.. JAMA network open. 4:-. 2021
15. Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020.. Journal of general internal medicine. 37:700-702. 2021
16. Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration. JAMA Internal Medicine. 2021
17. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. JAMA Network Open. 2020
18. Disagreements within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015. JAMA Network Open. 2020
19. Updating insights into rosiglitazone and cardiovascular risk through shared data: Individual patient and summary level meta-analyses 2020
20. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008–2015 2019
21. Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation 2019
22. Medicare part D spending on single-enantiomer drugs versus their racemic precursors. Annals of Internal Medicine. 2019
23. Regulatory review of new therapeutic agents - FDA versus EMA, 2011-2015. New England Journal of Medicine. 2017
24. The authors reply. New England Journal of Medicine. 2017
document